Roche has launched its Axelios gene sequencer, a new platform designed to perform large-scale DNA and RNA analysis, marking the company’s attempt to compete with industry leader Illumina. Roche aims to sell about 100 machines within the first year, targeting academic and research institutions to build a foundation for long-term growth in the $7.3 billion sequencing market.
How does the Axelios platform differ from existing technology?
Unlike traditional short-read sequencing systems, the Axelios platform converts genetic material into longer molecules. These molecules are processed through tiny pores on a reusable chip to generate data in near real time. By focusing on this method, Roche aims to support applications ranging from disease research to drug development.
To ensure adoption, Roche has secured partnerships for data analysis with 10x Genomics and Google DeepVariant. Early validation for the platform has been provided by the Broad Clinical Labs and the Hartwig Medical Foundation.
Roche’s launch comes more than a decade after the group’s failed $6.8 billion hostile bid to acquire Illumina.
What is the market outlook for Roche’s new sequencer?
Analysts anticipate a gradual push for market share rather than a rapid disruption. Illumina currently holds approximately 70% of the next-generation sequencing (NGS) market, according to industry estimates.
Vontobel analyst Stefan Schneider stated that Roche’s target of 100 machines in the first year is achievable due to the company’s commercial scale. However, Schneider noted that diagnostic product launches often experience slower adoption rates compared to medicines because of institutional tender processes.
How do pricing models affect laboratory adoption?
Roche has priced the Axelios instrument at $750,000 in the United States. This is competitive when compared to Illumina’s NovaSeq X machines, which list between $985,000 and $1.25 million.
Analysts note the upfront cost of the instrument is secondary to the recurring cost of supplies needed to run it, such as chemical reagents. These ongoing expenses can add up to millions of dollars over the lifespan of the machine.
When evaluating sequencing platforms, labs should prioritize the “total cost of ownership” rather than the initial hardware price, as reagent consumption often dictates the long-term budget impact of the technology.
Frequently Asked Questions
- Who is the primary target audience for the Axelios sequencer?
- The initial launch is restricted to academic and research-focused facilities.
- What is Roche’s long-term sales goal for this platform?
- The company intends to develop the Axelios into a blockbuster franchise, with the goal of generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
- Does the Axelios sequence DNA or RNA?
- The platform is designed to handle both DNA and ribonucleic acid (RNA) by converting them into longer molecules for easier reading.
Are you involved in genomic research or laboratory procurement? Share your thoughts on the impact of new sequencing platforms in the comments below, or subscribe to our newsletter for the latest updates on biotech industry developments.
